{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:01:45Z","timestamp":1784883705962,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Inher Metab Disea"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Untreated women with Gaucher disease (GD) are at an increased risk of GD\u2010related complications during pregnancy. Enzyme replacement therapy with imiglucerase is effective at improving hematologic, visceral, and bone manifestations of GD, and the Food &amp; Drug Administration prescribing information supports that imiglucerase is not associated with adverse maternal or fetal outcomes when used during pregnancy. This study population included women with GD enrolled in the International Collaborative Gaucher Group Gaucher Registry (NCT00358943) Pregnancy Sub\u2010Registry who were treated with imiglucerase during at least one pregnancy as of October 2023. We describe frequency of pregnancy outcomes, birth outcomes, and maternal and neonatal complications. Imiglucerase exposure was reported in 110 pregnancies in 68 women with GD type 1; 68% of pregnancies were exposed during all three trimesters. Of 104 fetuses with reported data, 92 were live births (88.5%), eight were spontaneous abortions (7.7%), and four were elective\/therapeutic terminations (3.8%); no stillbirths (&gt;\u200920\u2009weeks gestation) were reported. The majority of infants (80 of 85 [94.1%]) were born at term. Among 108 pregnancies with data, maternal pregnancy, labor and delivery, and post\u2010partum complications were reported for 33 (30.6%), 26 (24.1%), and 24 (22.2%) pregnancies, respectively, with anemia, thrombocytopenia, and vaginal bleeding among the most prevalent complications. Among 74 infants with data, neonatal complications were reported for seven infants (9.5%). Most pregnancies to women with GD treated with imiglucerase resulted in live births and healthy infants, with risk of spontaneous abortions similar to that of the general population (12%\u201318%).<\/jats:p>","DOI":"10.1002\/jimd.70161","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T03:25:56Z","timestamp":1771557956000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maternal and Fetal Outcomes in Imiglucerase\u2010Treated Patients With Gaucher Disease: Real\u2010World Evidence From the International Collaborative Gaucher Group (\n                    <scp>ICGG<\/scp>\n                    ) Gaucher Registry Pregnancy Sub\u2010Registry"],"prefix":"10.1002","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-0337","authenticated-orcid":false,"given":"Shoshana","family":"Revel\u2010Vilk","sequence":"first","affiliation":[{"name":"Gaucher Unit, The Eisenberg R&amp;D Authority Shaare Zedek Medical Center  Jerusalem Israel"},{"name":"Faculty of Medicine Hebrew University  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-9900","authenticated-orcid":false,"given":"Patrick","family":"Deegan","sequence":"additional","affiliation":[{"name":"Lysosomal Disorders Unit Addenbrooke's Hospital  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Day\u2010Salvatore","sequence":"additional","affiliation":[{"name":"Saint Peter's University Hospital Department of Medical Genetics and Genomic Medicine  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4758-6793","authenticated-orcid":false,"given":"Ozlem","family":"Goker\u2010Alpan","sequence":"additional","affiliation":[{"name":"Lysosomal &amp; Rare Disorders Research &amp; Treatment Center  Fairfax Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[{"name":"SphinCS\u2010Institute of Clinical Science for Lysosomal Storage Diseases  Hochheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie L.","family":"Batista","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny L.","family":"Carwile","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Perichon","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Ficicioglu","sequence":"additional","affiliation":[{"name":"The Children's Hospital of Philadelphia Division of Human Genetics and Metabolism  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000440865"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12881\u2010019\u20100759\u20101"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000002506"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2003.08.006"},{"issue":"2","key":"e_1_2_14_6_1","first-page":"7","article-title":"Worldwide Literature Review of Gaucher Disease and Pregnancy","volume":"6","author":"Day\u2010Salvatore D.","year":"1998","journal-title":"Gaucher Clinical Perspectives"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002\u20109378(95)91494\u20103"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2009.04.003"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.12.295"},{"key":"e_1_2_14_10_1","unstructured":"Genzyme Corporation \u201cCEREZYME (Imiglucerase): Prescribing Information \u201daccessed January 22 2025 https:\/\/products.sanofi.us\/cerezyme\/cerezyme.pdf."},{"key":"e_1_2_14_11_1","unstructured":"Genzyme Corporation \u201cCEREZYME (Imiglucerase): Summary of Product Characteristics \u201daccessed January 22 2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cerezyme\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010022\u201002517\u20100"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010122\u20101\u2010199501010\u201000005"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.06.021"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3734"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00682\u20106"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12382"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(08)60074\u20104"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239630"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocl.2021.11.003"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20104642(18)30139\u20101"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.003"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2010.12.024"},{"key":"e_1_2_14_24_1","unstructured":"Takeda Pharmaceuticals \u201cVPRIV (Velaglucerase alfa): Prescribing Information \u201daccessed January 23 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022575s030lbl.pdf."},{"key":"e_1_2_14_25_1","unstructured":"Pfizer \u201cELELYSO (Taliglucerase alfa): Prescribing Information \u201daccessed January 23 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022458s023lbl.pdf."},{"key":"e_1_2_14_26_1","unstructured":"Genzyme Corporation \u201cCERDELGA (Eliglustat): Prescribing Information \u201daccessed January 23 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021348s016lbl.pdf."},{"key":"e_1_2_14_27_1","unstructured":"Amicus Therapeutics \u201cOPFOLDA (Miglustat): Prescribing Information \u201daccessed January 23 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215211s002lbl.pdf."}],"container-title":["Journal of Inherited Metabolic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jimd.70161","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jimd.70161","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jimd.70161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:09:09Z","timestamp":1784880549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jimd.70161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/jimd.70161"],"URL":"https:\/\/doi.org\/10.1002\/jimd.70161","archive":["Portico"],"relation":{},"ISSN":["0141-8955","1573-2665"],"issn-type":[{"value":"0141-8955","type":"print"},{"value":"1573-2665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"2025-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70161"}}